Literature DB >> 12454289

Nonlymphoid Fas ligand in peptide-induced peripheral lymphocyte deletion.

Michael J Pinkoski1, Nathalie M Droin, Tesu Lin, Laurent Genestier, Thomas A Ferguson, Douglas R Green.   

Abstract

Peripheral lymphocyte deletion is required for reduction of lymphocyte numbers after expansion in response to antigen. Peripheral deletion is mediated in part by the activation of apoptosis by engagement of the death receptor, Fas (CD95), by its ligand, Fas ligand (FasL; CD95L), among other mechanisms. Here we used T cell receptor (TCR) transgenic animals to examine the role of inducible expression of nonlymphoid FasL in response to peptide antigen. Antigenic challenge of TCR transgenic mice resulted in increased expression of FasL in a number of nonlymphoid tissues including the epithelium of the small intestine. Similar results were obtained in an adoptive transfer system in which TCR transgenic T cells were transferred into recipient animals. The functional relevance of nonlymphoid FasL in peripheral deletion is supported by the observation that FasL-deficient gld animals showed a significantly reduced rate of clearance of transferred antigen-specific lymphocytes, although the lymphocytes themselves were wild type for FasL. These observations were supported further by studies in a transgenic mouse model where lacZ was expressed under the control of the proximal promoter of the FasL gene. Using these transgenic mice, we observed induced activity of the FasL promoter in intestinal epithelial cells throughout the crypts and villi, where we also observed infiltration of activated T cells. These data demonstrate that nonlymphoid FasL is expressed in response to peripheral T cell activation and participates in the regulation of T cells that infiltrate peripheral tissues.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12454289      PMCID: PMC138584          DOI: 10.1073/pnas.262660999

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  38 in total

1.  Preferential localization of effector memory cells in nonlymphoid tissue.

Authors:  D Masopust; V Vezys; A L Marzo; L Lefrançois
Journal:  Science       Date:  2001-03-01       Impact factor: 47.728

Review 2.  The liver as a site of T-cell apoptosis: graveyard, or killing field?

Authors:  I N Crispe; T Dao; K Klugewitz; W Z Mehal; D P Metz
Journal:  Immunol Rev       Date:  2000-04       Impact factor: 12.988

Review 3.  In vivo activation of antigen-specific CD4 T cells.

Authors:  M K Jenkins; A Khoruts; E Ingulli; D L Mueller; S J McSorley; R L Reinhardt; A Itano; K A Pape
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

4.  Visualizing the generation of memory CD4 T cells in the whole body.

Authors:  R L Reinhardt; A Khoruts; R Merica; T Zell; M K Jenkins
Journal:  Nature       Date:  2001-03-01       Impact factor: 49.962

5.  Murder by proxy.

Authors:  M J Pinkoski; D R Green
Journal:  Nat Immunol       Date:  2000-12       Impact factor: 25.606

6.  Testicular FasL is expressed by sperm cells.

Authors:  A D'Alessio; A Riccioli; P Lauretti; F Padula; B Muciaccia; P De Cesaris; A Filippini; S Nagata; E Ziparo
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

Review 7.  Mature T lymphocyte apoptosis--immune regulation in a dynamic and unpredictable antigenic environment.

Authors:  M Lenardo; K M Chan; F Hornung; H McFarland; R Siegel; J Wang; L Zheng
Journal:  Annu Rev Immunol       Date:  1999       Impact factor: 28.527

8.  TCR-mediated up-regulation of c-FLIPshort correlates with resistance toward CD95-mediated apoptosis by blocking death-inducing signaling complex activity.

Authors:  S Kirchhoff; W W Müller; A Krueger; I Schmitz; P H Krammer
Journal:  J Immunol       Date:  2000-12-01       Impact factor: 5.422

9.  Control of target cell survival in thyroid autoimmunity by T helper cytokines via regulation of apoptotic proteins.

Authors:  G Stassi; D Di Liberto; M Todaro; A Zeuner; L Ricci-Vitiani; A Stoppacciaro; L Ruco; F Farina; G Zummo; R De Maria
Journal:  Nat Immunol       Date:  2000-12       Impact factor: 25.606

Review 10.  Fas-FasL in Hashimoto's thyroiditis.

Authors:  G Stassi; A Zeuner; D Di Liberto; M Todaro; L Ricci-Vitiani; R De Maria
Journal:  J Clin Immunol       Date:  2001-01       Impact factor: 8.317

View more
  7 in total

1.  Defects in apoptosis increase memory CD8+ T cells following infection of Bim-/-Faslpr/lpr mice.

Authors:  Ashley E Weant; Ryan D Michalek; Katie E Crump; Chun Liu; Andrew P Konopitski; Jason M Grayson
Journal:  Cell Immunol       Date:  2011-07-24       Impact factor: 4.868

2.  Endothelial Fas-Ligand in Inflammatory Bowel Diseases and in Acute Appendicitis.

Authors:  Tuomo S Kokkonen; Tuomo J Karttunen
Journal:  J Histochem Cytochem       Date:  2015-09-15       Impact factor: 2.479

3.  Distinct roles of cytolytic effector molecules for antigen-restricted killing by CTL in vivo.

Authors:  Edith M Janssen; Ed E Lemmens; Naina Gour; Rachel A Reboulet; Douglas R Green; Stephen P Schoenberger; Michael J Pinkoski
Journal:  Immunol Cell Biol       Date:  2010-03-23       Impact factor: 5.126

Review 4.  Signals from dying cells: tolerance induction by the dendritic cell.

Authors:  Thomas A Ferguson; Hirotaka Kazama
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

5.  Egr family members regulate nonlymphoid expression of Fas ligand, TRAIL, and tumor necrosis factor during immune responses.

Authors:  Nathalie M Droin; Michael J Pinkoski; Emmanuel Dejardin; Douglas R Green
Journal:  Mol Cell Biol       Date:  2003-11       Impact factor: 4.272

6.  Protection from autoimmune diabetes and T-cell lymphoproliferation induced by FasL mutation are differentially regulated and can be uncoupled pharmacologically.

Authors:  Abdiaziz S Mohamood; Mehmet L Guler; Zuoxiang Xiao; Dongfeng Zheng; Allan Hess; Yi Wang; Hideo Yagita; Jonathan P Schneck; Abdel Rahim A Hamad
Journal:  Am J Pathol       Date:  2007-07       Impact factor: 4.307

7.  TNFalpha blockade prevents the development of inflammatory bowel disease in HLA-B27 transgenic rats.

Authors:  Anna Franca Milia; Mirko Manetti; Sergio Generini; Lucia Polidori; Gemma Benelli; Marina Cinelli; Luca Messerini; Lidia Ibba-Manneschi; Marco Matucci-Cerinic
Journal:  J Cell Mol Med       Date:  2008-03-19       Impact factor: 5.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.